Novo Nordisk stock popped Wednesday after its biggest moneymaker, a diabetes drug called Ozempic, put up a commanding fourth-quarter beat.

The post Novo Stock Surges Out Of A Buy Zone On Ozempic’s Commanding Sales Beat appeared first on Investor’s Business Daily.